Novel Cellular Therapies for Hepatocellular Carcinoma
Harriet Roddy, Tim Meyer, Claire Roddie
Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death worldwide. Most patients present with advanced disease, and current gold-standard management using tyrosine kinase inhibitors or immune checkpoint inhibitors (ICIs) offers modest clinical benefit. Cellular immune therapies targeting HCC are currently being tested in the laboratory and in clinical trials. Here, we review the landscape of cellular immunotherapy for HCC, defining antigenic targets, outlining the range of cell therapy products being applied in HCC (such as CAR-T and TCR-T), and exploring how advanced engineering solutions may further enhance this therapeutic approach.
Topics & Concepts
Hepatocellular carcinomaImmunotherapyMedicineClinical trialCancer researchImmune systemChimeric antigen receptorTyrosine kinaseCancer immunotherapyCancerOncologyImmunologyInternal medicineReceptorCAR-T cell therapy researchImmunotherapy and Immune ResponsesPhagocytosis and Immune Regulation